Prof. W Ray Kim
W. Ray Kim, MD is Professor of Medicine at the Mayo Clinic College of Medicine and Science and at Mayo Clinic Arizona.
Dr. Kim earned his medical diploma at Seoul National University. After moving to the US, he received his GI and hepatology training at Mayo Clinic College of Medicine. He rose through the ranks to be a Professor of Medicine at Mayo. In 2013, he moved to Stanford University to lead the Division of Gastroenterology and Hepatology. As Chief of the Division, he made numerous positive changes leading to a five-fold growth in the size of the faculty and trainees, an exponential increase in their academic productivity and undisputed standing as an academic center of excellence in the GI and liver community. In 2024, he returned to Mayo Clinic to found and direct the Center for Policy and Outcomes Research in Transplant (CPORT) and continue his research and mentorship.
Dr. Kim has been a leading figure in the American Association for the Study of Liver Disease. After serving as a member of its Governing Board, he was elected as President for 2024. He continues on the Governing Board as Past President.
Dr. Kim’s research interest has been in outcomes modeling in chronic liver disease. His research accomplishments include development of the Model for End Stage Liver Disease (MELD) and the Steatosis-Associated Fibrosis Estimator (SAFE) score. His research has produced >250 original publications to date with an h-index of >90.
Dr. Kim earned his medical diploma at Seoul National University. After moving to the US, he received his GI and hepatology training at Mayo Clinic College of Medicine. He rose through the ranks to be a Professor of Medicine at Mayo. In 2013, he moved to Stanford University to lead the Division of Gastroenterology and Hepatology. As Chief of the Division, he made numerous positive changes leading to a five-fold growth in the size of the faculty and trainees, an exponential increase in their academic productivity and undisputed standing as an academic center of excellence in the GI and liver community. In 2024, he returned to Mayo Clinic to found and direct the Center for Policy and Outcomes Research in Transplant (CPORT) and continue his research and mentorship.
Dr. Kim has been a leading figure in the American Association for the Study of Liver Disease. After serving as a member of its Governing Board, he was elected as President for 2024. He continues on the Governing Board as Past President.
Dr. Kim’s research interest has been in outcomes modeling in chronic liver disease. His research accomplishments include development of the Model for End Stage Liver Disease (MELD) and the Steatosis-Associated Fibrosis Estimator (SAFE) score. His research has produced >250 original publications to date with an h-index of >90.